Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2015

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

 

Amphastar Pharmaceuticals Reports Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2015

 

Reports Net Revenues of $76.9 Million for the Fourth Quarter Ended December 31, 2015

 

RANCHO CUCAMONGA, CA – March 14, 2016 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the fourth quarter and fiscal year ended December 31, 2015.

 

Fourth Quarter Highlights

 

·

Net revenues of $76.9 million for the fourth quarter

·

GAAP net income of $7.5 million, or $0.16 per diluted share for the fourth quarter

·

Adjusted non-GAAP net income of $9.1 million, or $0.19 per diluted share for the fourth quarter

 

Fiscal Year Highlights

 

·

Net revenues of $251.5 million for the fiscal year

·

GAAP net loss of $2.8 million, or $0.06 per diluted share, for the fiscal year

·

Adjusted non-GAAP net income of $2.9 million, or $0.06 per diluted share, for the fiscal year

 

Dr. Jack Zhang, Amphastar’s CEO, commented:  “We are pleased with the progress of our pipeline development and happy with recent acquisitions and product launches which diversify our portfolio and expand our vertical integration strategy.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Year Ended

 

 

 

December 31, 

 

December 31, 

 

 

 

2015

 

2014

 

2015

 

2014

 

 

 

(in thousands, except per share data)

 

Net revenues

    

$

76,912

    

$

55,877

    

$

251,519

    

$

210,461

 

GAAP net income (loss)

 

$

7,533

 

$

(2,521)

 

$

(2,787)

 

$

(10,699)

 

Adjusted non-GAAP net income (loss)*

 

$

9,074

 

$

(1,496)

 

$

2,895

 

$

(5,003)

 

GAAP diluted EPS

 

$

0.16

 

$

(0.06)

 

$

(0.06)

 

$

(0.25)

 

Adjusted non-GAAP diluted EPS*

 

$

0.19

 

$

(0.03)

 

$

0.06

 

$

(0.12)

 


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Monday, March 14, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Condensed Consolidated Statements Of Cash Flows
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statements Of Comprehensive Income (loss)
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (parentheticals)
Business Acquisition
Business Acquisition (details 2)
Business Acquisition (details 3)
Business Acquisition (details 4)
Business Acquisition (details 5)
Business Acquisition (details)
Business Acquisition (tables)
Commitments And Contingencies
Commitments And Contingencies (details 2)
Commitments And Contingencies (details 3)
Commitments And Contingencies (details 4)
Commitments And Contingencies (details 5)
Commitments And Contingencies (details 6)
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Customer And Supplier Concentration
Customer And Supplier Concentration (details)
Customer And Supplier Concentration (tables)
Debt
Debt (details 2)
Debt (details 3)
Debt (details)
Debt (tables)
Document And Entity Information
Employee Benefits
Employee Benefits (details)
Fair Value Measurements
Fair Value Measurements (details 2)
Fair Value Measurements (details)
Fair Value Measurements (tables)
General
Goodwill And Intangible Assets
Goodwill And Intangible Assets (details 2)
Goodwill And Intangible Assets (details 3)
Goodwill And Intangible Assets (details 4)
Goodwill And Intangible Assets (details 5)
Goodwill And Intangible Assets (details)
Goodwill And Intangible Assets (tables)
Impairment Of Long-lived Assets
Impairment Of Long-lived Assets (details)
Income (loss) Per Share
Income (loss) Per Share (details 2)
Income (loss) Per Share (details)
Income (loss) Per Share (tables)
Income Taxes
Income Taxes (details 2)
Income Taxes (details 3)
Income Taxes (details 4)
Income Taxes (details 5)
Income Taxes (details 6)
Income Taxes (details 7)
Income Taxes (details 8)
Income Taxes (details 9)
Income Taxes (details)
Income Taxes (tables)
Inventories
Inventories (details)
Inventories (tables)
Litigation
Litigation (details)
Property, Plant, And Equipment
Property, Plant, And Equipment (details 2)
Property, Plant, And Equipment (details)
Property, Plant, And Equipment (tables)
Quarterly Financial Data
Quarterly Financial Data (unaudited) (tables)
Quarterly Financial Data (unaudited) - Quarterly Financial Data (details) (imported)
Revenue Recognition
Revenue Recognition (details 2)
Revenue Recognition (details 3)
Revenue Recognition (details)
Revenue Recognition (tables)
Segment Reporting
Segment Reporting (details 2)
Segment Reporting (details 3)
Segment Reporting (details)
Segment Reporting (tables)
Stockholders' Equity
Stockholders' Equity (details 10)
Stockholders' Equity (details 11)
Stockholders' Equity (details 2)
Stockholders' Equity (details 3)
Stockholders' Equity (details 4)
Stockholders' Equity (details 5)
Stockholders' Equity (details 6)
Stockholders' Equity (details 7)
Stockholders' Equity (details 8)
Stockholders' Equity (details 9)
Stockholders' Equity (details)
Stockholders' Equity (tables)
Subsequent Events
Subsequent Events (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (schedule Of Pp&e Useful Lives) (details)
Summary Of Significant Accounting Policies (summary Of Intangible Assets Useful Lives) (details)
Summary Of Significant Accounting Policies (summary Of Self-insured Claims) (details)
Summary Of Significant Accounting Policies (tables)
Ticker: AMPH
CIK: 1297184
Form Type: 10-K Annual Report
Accession Number: 0001558370-16-004146
Submitted to the SEC: Tue Mar 15 2016 2:08:18 PM EST
Accepted by the SEC: Tue Mar 15 2016
Period: Thursday, December 31, 2015
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001558370-16-004146.htm